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cDepartment of Pharmacological and Biomolecular Sciences, Universita` degli Studi di Milano, Milan, ItalyAbstractLow high density lipoprotein cholesterol (HDL-C) levels represent an independent risk factor for cardiovascular disease; in addition to
the reduced HDL-C levels commonly observed in patients at cardiovascular risk, the presence of dysfunctional HDL, i.e. HDL with reduced
atheroprotective properties, has been reported. Despite the established inverse correlation between HDL-C levels and cardiovascular risk,
several clinical trials with HDL-C-increasing drugs (such as niacin, CETP inhibitors or fibrate) failed to demonstrate that a significant rise
in HDL-C levels translate into a cardiovascular benefit. Statins, that are the most used lipid-lowering drugs, can also increase HDL-C levels,
although this effect is highly variable among studies and statins; the most recent developed statin, pitavastatin, beside its role as LDL-C-
lowering agent, increases HDL-C levels at a significantly higher extent and progressively upon treatment; such increase was observed also
when patients where shifted from another statin to pitavastatin. The stratification by baseline HDL-C levels revealed that only pitavastatin
significantly increased HDL-C levels in patients with baseline HDL-C 45 mg/dl, while no changes were observed in patients with higher
baseline HDL-C levels. In the last years the hypothesis that functional properties of HDL may be more relevant than HDL-C levels has risen
from several observations. The treatment with pitavastatin not only increased HDL-C levels, but also increased the phospholipid content of
HDL, increased the HDL efflux capacity and their anti-oxidant properties. These observations suggest that, besides its high LDL-C-
lowering effect, pitavastatin also exhibits a significantly higher ability to increase HDL-C levels and may also positively affect the
quality and functionality of HDL particles.
 2017 Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The role of statins in the reduction of low density lipo-
protein cholesterol (LDL-C) levels and in the prevention of
cardiovascular disease has been largely established.
However, despite large reduction of LDL-C plasma levels,
patients still experience cardiovascular events, due to the
“residual risk” related to factors other than LDL-C levels
that include other lipid anomalies, such as low HDL-C and* Corresponding author. Department of Pharmacological and Biomolecular
Sciences, University of Milan, Via Balzaretti, 9, 20133, Milan, Italy. Fax:
þ39250318386.
E-mail address: alberico.catapano@unimi.it (A.L. Catapano).
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.001
1567-5688/ 2017 Elsevier B.V. This is an open access article under the CC BYhigh triglyceride levels, or the presence of pathological
conditions such as diabetes or metabolic syndrome [1].
Low HDL-C levels is a well-established independent risk
factor for atherosclerosis-related disease [2,3], mainly due
to the many atheroprotective properties of this class of
lipoproteins, suggesting that increasing HDL-C levels
should reduce the cardiovascular risk. However, the failure
of some clinical trials to demonstrate that increasing HDL-
C levels reduced the cardiovascular events [4e9], and data
from genetic studies [10] challenged the “HDL hypothesis”
and suggested that the improvement of HDL particle
function would be more important than simply increase
their plasma levels [11].
Statins are the most widely used LDL-C-lowering drugs
and clinically increase also HDL-C levels, although a great-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2. Anti-atherogenic properties of HDL.
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has a LDL-C-lowering effect similar or even superior to
that of other statins, but a significantly higher ability to
increase HDL-C levels [13e15] and may also positively
affect the quality and functionality of HDL particles. In the
present review we focus our attention on this peculiar effect
of pitavastatin in comparison with other statins and discuss
both the effect on HDL-C levels and HDL functionality.
2. Pitavastatin: a general overview
Pitavastatin is a synthetic lipophilic statin with a unique
structure (Fig. 1), compared with other statins, that deter-
mines an increased oral absorption and systemic bioavail-
ability [16], as well as an increased affinity for HMG-CoA
reductase [17] and strong effects on plasma LDL-C and
HDL-C levels [18]. Pitavastatin undergoes limited metab-
olism, as it is poorly metabolized by cytochrome P450
(CYP) 2C9 [19] (Fig. 1). This can explain the lack of
increase in the incidence of muscle-related adverse events
in patients treated with pitavastatin and drugs known to
affect CYP isoenzymes, even when considering drugs
interacting with CYP2C9 that is minimally involved in the
metabolism of pitavastatin [20]. Furthermore, the P-
glycoprotein transporter does not play a major role in pit-
avastatin disposition, and pitavastatin does not inhibit P-
glycoprotein activity, thus it is unlikely that pitavastatin
plasma levels may be affected by concomitant use of P-
glycoprotein inhibitors [21]. Pitavastatin may, however,
interact with other transporters systems, such as the organic
anion transporting polypeptide OATP1B1, responsible for
its uptake into hepatocytes [22]. This implies that pit-
avastatin may interact with various drugs through these
transporters [23] (Fig. 1). However, the available data from
clinical trials and post-marketing surveillance suggest that
concomitant administration of pitavastatin with other drugs
was associated with a low incidence of adverse events due
to drugedrug interactions [20], in agreement with data
obtained in healthy volunteers [24e27], indicating this
drug as helpful for the treatment of high-risk patients who
receive concomitant therapies Fig. 2.
Several clinical trials have suggested the possibility that
statin therapy may increase the risk of incident type 2
diabetes (T2D) [28e30]. In this context, pitavastatin seems
to have a neutral and possibly beneficial effect on glucoseFig. 1. Chemical structure and metabhomeostasis, as it was not associated with significant
changes in fasting plasma glucose, glycated haemoglobin,
insulin or homeostasis model assessment index [31e33]. A
recent meta-analysis of 15 randomized controlled clinical
trials reported that pitavastatin therapy was not associated
with increased fasting blood glucose, HbA1c or new-onset
diabetes in non-diabetic patients [34]. Most trials (11 out of
15) included in this meta-analysis had a short follow-up (12
weeks), while it is known that the exposure time to a statin
may influence the risk to have glucose-related anomalies;
however no significant differences were observed between
short-term and longer-term (32e120 weeks) treatments
[34]. In fact the CAPITAIN study, performed in healthy
subjects with metabolic syndrome showed that a 6-month
treatment with the highest available dose of pitavastatin
(4 mg/day) did not alter significantly parameters related to
glucose or insulin metabolism [31] and a subanalysis of the
LIVES study showed a significant 0.28% (p < 0.001)
reduction of HbA1c in diabetic patients treated with pit-
avastatin for 104 weeks [35]. These results seem to suggest
that the diabetogenic effect of statins is not a class effect
and that pitavastatin may be specifically useful in patients
at risk of developing diabetes, such as those with metabolic
syndrome. The J-PREDICT (Japan Prevention Trial of
Diabetes by Pitavastatin in Patients with Impaired Glucose
Tolerance) study was designed to specifically address this
issue, as it evaluated the cumulative incidence of new-onset
diabetes in patients with impaired glucose tolerance treated
with pitavastatin 1e2 mg/day in combination with lifestyleolic pathways of pitavastatin.
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been completed in 2015 and we are waiting for final results.
Preliminary data showed a lower diabetes incidence rate in
the pitavastatin group compared with the only lifestyle
modification group [36]. Pitavastatin is the only statin able
to increase plasma levels of adiponectin, a protein pos-
sessing anti-atherosclerotic, anti-inflammatory and anti-
diabetogenic properties, which might explain, at least in
part, the neutral or even beneficial effect of pitavastatin on
glucose metabolism [37], although other mechanisms
cannot be excluded. These findings suggest that pitavastatin
may be a useful treatment for patients with type 2 diabetes
or at risk to develop diabetes, although a long-term evalu-
ation of the diabetogenic effect of pitavastatin is still
lacking.
3. HDL: role in cardiovascular disease and findings
from clinical trials
HDL is believed to be protective toward the develop-
ment of atherosclerosis possibly via the process of reverse
cholesterol transport, i.e. the removal of excess cholesterol
from peripheral tissues to the liver for excretion; both lipid-
poor apolipoprotein A-I (the main apoprotein of HDL) and
mature HDL contribute to this process [38]. In addition to
this, HDL possesses several other functions, including anti-
inflammatory and anti-oxidative activities, as well as
immuno-modulatory and innate host defense properties
[38e40] (Fig. 1). HDL is highly heterogeneous and
comprises several subfractions having different size,
composition and functions, and several lipolytic enzymes
as well as lipid exchange proteins are involved in the
remodelling of HDL particles [38].
HDL-C levels inversely correlate with the risk of coro-
nary artery disease (CAD) [2,3], and low HDL-C levels,
that are common in patients with high cardiovascular risk,
remain significantly and independently associated with
increased CAD risk also in statin-treated patients [41].
Despite this inverse relationship, and although several
therapeutic options are available to increase HDL-C levels,
most of the clinical trials failed to demonstrate that an
increase of HDL-C results in a reduction of cardiovascular
risk. This occurred in trials with either niacin [4,5], CETP
inhibitors [6e8] or fenofibrate [9], although a reduction of
CV events was observed in subgroups of patients with low
baseline HDL-C levels and high TG when treated with
fibrates [9,42]. A possible explanation for the failure in the
remaining study population could be that these therapies,
while increasing HDL-C levels, do not restore or improve
the functionality of HDL particles that may become
dysfunctional (which includes loss of physiological func-
tion and gain of pathological dysfunction) under acute and
chronic inflammatory conditions, including dyslipidemia
and atherosclerosis-related conditions [43]. On the other
hand, despite the significant cardiovascular protection,
patients treated with statins still experience cardiovascularevents, referred to as “residual risk”, present also during
intensive lipid-lowering treatments. Such residual risk is, at
least in part, linked to several conditions other than LDL-C
levels, including high levels of triglycerides, low levels of
HDL-C, presence of diabetes, hypertension, and obesity, all
of which are independent risk factors for CAD. It is known
that statins can increase plasma concentrations of HDL-C,
although modestly and with great variability among
studies and different statins [44,45]. The extent of HDL
increase seems to be mainly related to the baseline levels of
HDL-C, being low HDL-C levels associated with a higher
percent increase during statin therapy, while patients with
higher HDL-C levels (w60 mg/dL) show no or marginal
increase [46,47].
In contrast with the findings obtained in clinical studies
with HDL-raising drugs, clinical trials evaluating the
effects of increasing HDL-C levels during statin therapy
have shown a reduction of cardiovascular events. A post
hoc analysis of the Treating to New Target (TNT) study
showed that HDL-C levels during statin treatment were
predictive of major cardiovascular events, and even among
subjects with LDL-C below 70 mg/dL, those in the highest
quintile of HDL-C levels had a lower cardiovascular risk
than those in the lowest quintile [1]. Similarly, in hyper-
cholesterolemic patients treated with low dose simvastatin
(5e10 mg/day), which induced a 4.5% average percent
increase in HDL-C levels over a period of 6 years, the
mortality rate was higher in patients with HDL-C levels
below 40 mg/dl than in those with levels above 50 mg/dl
[48]. In addition, statin therapy induced coronary artery
atheroma regression when LDL-C was significantly
reduced and HDL-C increased by more than 7.5% [49],
suggesting that statin benefit may derive from both LDL-C
reduction and HDL-C increase.
4. The clinical impact of pitavastatin: focus on HDL-C
Several clinical trials have demonstrated the ability of
pitavastatin to improve the lipid profile in patients with
primary hypercholesterolemia or combined dyslipidemia,
with an efficacy comparable or even superior to that of
other statins including atorvastatin, simvastatin or pravas-
tatin [50e54]. However, although statins have generally
only a modest and variable effect on HDL, pitavastatin has
unique pharmacological features that result in a clinically
significant reproducible increase of HDL-C levels (Table 1)
[14,15,52]. Such an effect may be particularly relevant in
some groups of patients, such as those with type 2 diabetes
or metabolic syndrome, as they usually have low HDL-C
levels in addition to high LDL-C and TG levels [55]. The
J-LIT study showed, in fact, that an increase of 10 mg/dL
(0.26 mmol/L) of HDL-C levels translated into a 34.9%
reduction in the risk of coronary events in patients with
both hypercholesterolemia and type 2 diabetes [56]. Clin-
ical studies have also shown that increasing HDL-C levels
by statins significantly decreases the progression of
Table 1
Effect of pitavastatin on HDL-C and apoA-I levels in different groups of patients.
Baseline characteristics
of patients (Ref.)
Interventions Duration Effects on HDL-C levels (% change)
LDL-C140 mg/dl
Glucose intolerance
(Sasaki et al., 2008) [13]
Pitavastatin 2 mg/day
Atorvastatin 10 mg/day
52 weeks HDL-C:
Pitavastatin þ8.2%; p ¼ 0.031 vs Atorvastatin
Atorvastatin: þ2.9%
ApoA-I:
Pitavastatin: þ5.1%; p ¼ 0.019 vs Atorvastatin
Atorvastatin:þ0.6%
Stable CAD;
LDL-C>100 under statin or
LDL-C>140 without LLT;
HDL-C<40 mg/dl
(Kurogi et al., 2013) [61]
Pitavastatin 2e4 mg/day
Atorvastatin 10e20 mg/day
30 months HDL-C:
Pitavastatin: þ20.1%; p ¼ 0.013 vs Atorvastatin
Atorvastatin: þ6.3%
ApoA-I:
Pitavastatin: þ20.84%; p ¼ 0.034 vs Atorvastatin
Atorvastatin: þ11.36%
LDL-C >130, <220 mg/dl
TG  400 mg/dl
(Sponseller et al., 2014) [62]
Pitavastatin 4 mg
Pravastatin 40 mg
12 weeks HDL-C:
Pitavastatin: þ6.3%; p ¼ 0.101 vs Pravastatin
Pravastatin: þ5.2%
Hypercholesterolemia or FH
(Teramoto et al., 2009) [14]
Pitavastatin (1e4 mg)
(de novo or switch from
other statins or
lipid-lowering drugs)
104 weeks All patients: HDL-C, þ5.9%; p < 0.0001 vs baseline
Baseline HDL-C<40 mg/dl: HDL-C, þ24.6%;
p < 0.0001 vs baseline
De novo pitavastatin: All patients: þ6.5%; p < 0.01 vs baseline;
Baseline HDL-C<40 mg/dl: þ27.3%; p < 0.01 vs baseline
Switch from other LLT: All patients: þ3.8%;
p < 0.01 vs baseline;
Baseline HDL-C<40 mg/dl: þ19.8%; p < 0.01 vs baseline
Switch from:
Pravastatin: All patients: þ3.9%; p < 0.01 vs baseline
Baseline HDL-C<40 mg/dl: þ21.0%; p < 0.01 vs baseline
Simvastatin: All patients: þ5.5%; p < 0.01 vs baseline
Baseline HDL-C<40 mg/dl: þ11.8%; ns
Fluvastatin: All patients: þ5.3%; p < 0.01 vs baseline
Baseline HDL-C<40 mg/dl: þ20.1%; ns
Atorvastatin: All patients: þ2.9; p < 0.01 vs baseline;
Baseline HDL-C<40 mg/dl: þ15.8%; p < 0.01 vs baseline
Other LLT: All patients: þ3.5%;
Baseline HDL-C<40 mg/dl: þ9.2%
Dyslipidemic treated with
Pitavastatin 2 mg/day or
Atorvastatin 10 mg/day or
Rosuvastatin 2.5 mg/day
(Kakuda et al., 2014) [64]
Switch to another statin 3 months ATO/PIT: HDL-C: þ7.69%; p ¼ 0.001 vs baseline
ApoA-I: þ6.69%; p ¼ 0.0047 vs baseline
PIT/ATO: HDL-C: 5.56%; p ¼ 0.0290 vs baseline
ApoA-I: 4.5%; p ¼ 0.0342 vs baseline
ROS/PIT: HDL-C: þ7.53%, p ¼ 0.0004 vs baseline
ApoA-I: 4.85%, p ¼ 0.0122 vs baseline
Hypercholesterolemic
(Teramoto et al., 2011) [67]
Pitavastatin 1, 2 and 4 mg 5 years All patients: þ5.7%; p < 0.001 vs baseline
Subgroup analysis:
Low baseline HDL-C: þ28.9%; p < 0.001 vs baseline
Low baseline HDL-C þ diabetes: þ26.7%;
p < 0.001 vs baseline
Low baseline HDL-C þ IHD: þ22.5%;
p < 0.001 vs baseline
Post-PCI patients
(Maruyama et al., 2011) [15]
Statins All patients:
No statin: þ5.3%
Pravastatin: þ5.4%; ns
Atorvastatin: þ7.0%; ns
Pitavastatin: þ13.4%; p ¼ 0.01 vs no statin group
Baseline HDL-C 45 mg/dl:
No statin: þ9.7%
Pravastatin: þ13.6%
Atorvastatin: þ14.5%
Pitavastatin: þ21.3%; p < 0.001 vs no statin group
CAD: coronary artery disease; LLT: lipid-lowering treatment; PCI: percutaneous coronary intervention. Only statistically significant p values were reported.
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brovascular risk independently of LDL-C levels
[49,57e60].4.1. Comparison between pitavastatin and other
statinsPatients with high baseline LDL-C levels and glucose
intolerance were given pitavastatin (2 mg/day) or atorvas-
tatin (10 mg/day) and followed for 52 weeks [13]. Pit-
avastatin increased HDL-C and apoA-I more than
atorvastatin (difference in % change, pitavastatin vs ator-
vastatin: þ5.3%, p ¼ 0.031 and þ4.5%, p ¼ 0.019,
respectively) [13]. Similar observations were reported in
the COMPACT-CAD study in which patients with stable
coronary artery disease, hypercholesterolemia and low
HDL-C levels (<50 mg/mL) were treated with pitavastatin
2e4 mg/day or atorvastatin 10e20 mg/day for 30 months
[61]. Despite similar reductions in LDL-C levels, percent
changes in HDL-C levels were significantly greater with
pitavastatin than with atorvastatin (þ20.1  25.7% and
6.3  19.8%, respectively, p ¼ 0.01), with similar results in
apoA-I levels [61]. Contrarily to what was observed with
atorvastatin, the increase of HDL-C levels induced by pit-
avastatin was progressive and continuous during the follow-
up period [61]. When compared with pravastatin in patients
with primary hypercholesterolemia or combined dyslipi-
demia, both treatments significantly (p < 0.001) increased
HDL-C (pitavastatin 4 mg: þ6.3%, pravastatin 40 mg:
þ5.2%) after 12 weeks without difference between the two
statins [62]. A possible explanation for these disagreeing
findings may be related to the time of treatment: in fact, in
the study by Kurogi et al. [61] the difference between pit-
avastatin and atorvastatin on HDL-C levels started to
become evident after 12 months treatment and were
significantly different at 30 months. This may suggest that,
due to the progressive and continuous increase of HDL over
time following treatment with pitavastatin, a long-term
therapy with pitavastatin may be required to observe its
specific effect on HDL-C levels.
The LIVALO Effectiveness and Safety Study (LIVES
Study) followed hypercholesterolemic patients treated with
pitavastatin for 2 years, showing a significant 7.5%
(p < 0.05) increase of HDL-C levels, with a 24.9%
(p < 0.001) increase in the subgroup with low baseline
HDL-C levels (<40 mg/dL) [14]. In contrast with LDL-C
levels, that showed a dramatic decrease after 12 weeks
and then remained constantly low, HDL-C levels gradually
and continuously increased in the course of the follow-up
period [14,63]. Although statin-naı¨ve patients showed the
highest increase, a significant rise of HDL-C levels was
observed also in patients who had been taking cholesterol-
lowering drugs other than pitavastatin, with increases after
switch from atorvastatin or rosuvastatin to pitavastatin
(þ7.7%, p ¼ 0.0010 and þ7.5%, p ¼ 0.0004, respectively)
and reduction in patients switched from pitavastatin toatorvastatin (5.6%, p ¼ 0.029) [64], thus confirming the
observations of previous studies [14,65,66]. The LIVES
Study Extension, which followed patients for an additional
3 years, confirmed a 5.7% increase of HDL-C in the whole
study population, with higher increases in subgroups of
patients such as those with low baseline HDL-C levels
(<40 mg/dL; þ28.9%  38.1, p < 0.001) as well as in
those with low HDL-C associated with either diabetes
(þ26.7%  27.5, p < 0.001) or history of ischemic heart
disease (þ22.5%  27.3, p < 0.001) [67]. Interestingly, the
KaplaneMeier curves showed that the cumulative inci-
dence of total (cardiovascular þ cerebrovascular) events
was higher in patients who achieved only LDL-C or HDL-
C treatment goals compared with those who achieved both
treatment goals [67].
The CIRCLE study confirmed these findings, showing
that pitavastatin and atorvastatin more efficiently decreased
LDL-C levels in patients who underwent percutaneous
coronary intervention compared with pravastatin [15];
however, the increment of HDL-C was much higher with
pitavastatin than with the other statins, and the incidence of
major adverse cardiac events were significantly lower in the
pitavastatin group than in the other groups (8.3% with
pitavastatin, 19.3% with atorvastatin, 27.2% with pravas-
tatin and 35.1% in the placebo group) [15]. The analysis
based on the baseline HDL-C values revealed that, despite
similar reductions in LDL-C levels, only patients with
baseline HDL-C levels 45 mg/dL experienced an increase
in HDL-C levels, and that pitavastatin was the most
effective statin [15]. The incidence of cardiac events in the
various groups reflected this finding, being patients with
baseline HDL-C levels 45 mg/dL treated with pitavastatin
those with the lowest incidence of major adverse cardio-
vascular events [15]. This finding suggests that a thera-
peutic intervention focused on both LDL-C and HDL-C
levels may be beneficial and that pitavastatin may play
a special role, especially in patients with low baseline
HDL-C levels.
5. Possible mechanisms of the pitavastatin-induced
effects on HDL
Circulating levels of HDL are determined by the balance
between production and catabolism. One mechanism by
which pitavastatin increases HDL-C levels is by inducing
the production and secretion of hepatic apoA-I [68] (Table
2); such induction was more marked with pitavastatin than
with other statins (simvastatin or atorvastatin) [68]. Pit-
avastatin also increases ABCA1 expression [68,69] (Table
2); since ABCA1 plays a key role in the lipidation of
apoA-I to generate HDL particles and in protecting apoA-I
from catabolism, its induction by pitavastatin may
contribute to the increased secretion of hepatic apoA-I [68].
The apoA-I induction by pitavastatin is related to the
inhibition of cholesterol synthesis pathway, as suggested by
the inhibitory effect of mevalonate addition [68];
Table 2
Possible mechanisms by which pitavastatin increases HDL quality and function.
Reference System Effects
Maejima et al., 2004 [68] HepG2 [apoA-I production and secretion
Maejima et al., 2011 [69] HepG2 [ABCA1 mRNA expression
Han et al., 2004 [71] J774, mouse peritoneal macrophages,
human monocyte-derived macrophages
[SR-BI expression/[macrophage
HDL binding
[ cholesterol efflux
[ cholesteryl ester influx
Kojima et al., 2010 [72] HUVEC
Mouse aorta and liver
Patients with cardiovascular disease
YEL expression
YEL expression
[HDL particle size
Y plasma EL levels
[HDL particle size
Miyamoto-Sasaki et al., 2013 [75] Dyslipidemic subjects treated with
pitavastatin 2 mg/day for 4 weeks
[ HDL-C levels
[PL content in HDL
[large HDL particle number
[HDL-mediated efflux
[PON-1 activity
Kawano et al., 2008 [76] Hypercholesterolemic patients treated
with pitavastatin 2 mg/day for 4 weeks
[HDL2-C
Ypreb-HDL levels; [preb-HDL
disappearance rate
YLCAT activity
YCETP mass
Orsoni et al., 2016 [78] Insulin-resistant, HTG, hypertensive obese
male patients treated with pitavastatin
4 mg/day for 6 months
YTG content in HDL2 and HDL3
[CE content in HDL2 and HDL3
[PE plasmalogens and PUPC in HDL3
Igarashi et al., 2007 [81] BAEC [S1P1 receptors
[HDL-mediated eNOS stimulation
HUVEC: human umbilical vein endothelial cells; ABCA1: ATP-binding cassette transporter A1; SR-BI: scavenger receptor class B type I; EL: endothelial
lipase; PL: phospholipids; PON1: paraoxonase 1; LCAT: lecithin-cholesterol acyltransferase; CETP: cholesteryl ester transfer protein; TG: triglyceride; CE:
cholesteryl ester: PE: phosphatidylethanolamine; PUPC: polyunsaturated phosphatidylcholines; BAEC: bovine aortic endothelial cells; S1P1: sphingosine-1-
phosphate subtype 1 receptor; eNOS: endothelial nitric oxide synthase.
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more effectively than simvastatin and atorvastatin, respec-
tively, which may explain the greater increase of apoA-I
secretion compared with the other two statins [68].
Furthermore, pitavastatin increased the expression of
macrophage scavenger receptor class B type I (SR-BI),
a HDL receptor involved in the reverse cholesterol trans-
port process [70], resulting in increased binding of HDL to
macrophages and enhanced efflux of free cholesterol to
HDL and uptake of cholesteryl ester/HDL by cells [71]
(Table 2).
Another mechanism by which pitavastatin increases
HDL-C levels is through the inhibition of endothelial lipase
(EL) [72] (Table 2). EL, whose expression is increased by
pro-inflammatory stimuli, is a negative regulator of HDL-C
levels; in fact, by hydrolyzing phospholipids, EL destabi-
lizes HDL particles thus resulting in an enhanced catabo-
lism [73]; EL inhibition increases both HDL-C levels and
HDL particle quality, as it generates HDL endowed with
increased anti-inflammatory, antioxidative and cholesterol
effluxing properties [74] (Fig. 1). Pitavastatin was shown to
suppress basal and cytokine-induced expression of EL in
cultured endothelial cells and decreased EL expression in
mouse aorta and liver [72]. Moreover, pitavastatin reduced
plasma EL in hypercholesterolemic patients by 14%,increased HDL-C levels by 11% and HDL particle size by
12% due to increase of phospholipid content [72], an effect
that was independent of the changes in plasma LDL-C
levels. This suggests that pitavastatin not only increases
the quantity of HDL, but may also improve the quality, and
thus function, of HDL. In fact, dyslipidemic patients treated
with pitavastatin for 4 weeks showed a significant increase
in HDL-C levels compared with baseline levels
(55.3  11.4 vs 50.7  11.4, p  0.01) as well as HDL-
phospholipids levels (þ7.8%, p ¼ 0.047) [75]; the
number of large HDL particles increased after pitavastatin
treatment [75] (Table 2). Pitavastatin treatment also resul-
ted in an increased capacity of cholesterol efflux of isolated
HDL and in increased activity of the antioxidant HDL-
associated enzyme paraoxonase-1 (PON-1) [75] (Table 2).
The observations suggest that pitavastatin increases the
serum levels of HDL-C but also increases the anti-
atherogenic properties of HDL particles.
Some studies have also evaluated the effect of pit-
avastatin treatment on HDL subfractions. Hypercholester-
olemic patients treated with 2 mg/day pitavastatin showed
a 6% increase of HDL-C levels after 4 weeks and a 9%
HDL2-C levels increase [76]. Preb1-HDL is the main
cholesterol acceptor during the initial step of reverse
cholesterol transport, and thus its plasma concentration
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cells; thus high plasma levels of preb1-HDL level may
reflect an impaired ability of cells to efflux cholesterol and
may represent a marker of cardiovascular risk [77].
Following treatment with pitavastatin, preb1-HDL was
significantly reduced (8.7%, p < 0.05), possibly due to an
increased disappearance rate, suggesting that pitavastatin
may promote the early step of reverse cholesterol transport,
thus possibly explaining also the increase of the largest
HDL2 particle [76]. Recently it was shown that in dysli-
pidemic patients with metabolic syndrome recruited for the
CAPITAIN (An Open Label Study of the Chronic and
Acute Effects of Pitavastatin on Monocyte Phenotype,
Endothelial Dysfunction and HL Atheroprotective Function
in Subjects with Metabolic Syndrome) study, pitavastatin,
although without significant effects on total HDL levels
(þ4%) or HDL2 and HDL3 levels (7% and þ8%,
respectively) after a 6-month treatment, had a positive
impact on the antioxidant capacity of HDL [78]. In fact,
pitavastatin treatment reduced the content of oxidizable
polyunsaturated phosphatidylcholine (PC) species contain-
ing docosahexaenoic acid and linolenic acid in LDL,
increased the content of PC and phosphatidylethanolamine
plasmalogens containing arachidonic acid and docosahex-
aenoic acid in small dense HDL3 [78]; furthermore, it
induced the formation of HDL3 with increased ability to
inactivate redox-active phospholipid hydroperoxides
PCOOH to redox-inactive PCOH [78]. This results in an
attenuated propagation of lipid peroxidation and reduced
formation of potentially atherogenic secondary oxidation
products [78], suggesting a potential anti-inflammatory
effect of pitavastatin treatment.
Statins also play a relevant role in establishing the
normal endothelial function and increasing the bioavail-
ability of nitric oxide (NO) [79]. Sphingosine-1-phosphate
(S1P), a bioactive sphingolipid associated with HDL, plays
a relevant role in the production of NO by endothelial NO
synthase [80]; pitavastatin was shown to upregulate the
expression of S1P1 receptor in cultured endothelial cells
more than atorvastatin and pravastatin, and this resulted in
an increased eNOS activation upon stimulation with HDL
[81].
6. Possible implications and conclusions
Specific studies are required to establish whether
pitavastatin-induced HDL-C level increase may result in
a positive clinical impact. To date, some data seem to
suggest that this could be the case. For example, it was
shown that a 12-month pitavastatin treatment slightly but
significantly reduced mean carotid intimaemedia thickness
(IMT) in patients with coronary heart disease, an effect that
was observed significantly more frequently in subjects with
high on-treatment HDL-C levels than in those with low
HDL-C levels (P ¼ 0.017) and tended to be inversely
correlated with increments in HDL-C and apoA-I [82]. Awave of skepticism has recently come into the HDL
hypothesis, mainly based on the data from CETP inhibitors
[6,7,83,84]. It should be reminded however that targeting
CETP is one of the several mechanisms by which HDL-C
could be increased, and these failures may not be extrap-
olated to targeting other mechanisms (as an example
increase apoA-I production rate).
The effect of pitavastatin on HDL needs further evalu-
ation and may prove ultimately beneficial, yet more data
need to be gathered to support these promising findings.
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